Quantity of eligible clients: CDEC mentioned the uncertainty in the quantity of clients with moderately significant to severe hemophilia B in Canada suitable for etranacogene dezaparvovec. Scientific experts consulted by CADTH indicated that some sufferers who're labeled as getting moderate or moderate illness could have a intense bleeding phenotype, which https://hemgenix95936.snack-blog.com/35762532/the-best-side-of-hemgenix